News Observation: Cracking the "Expensive To See a Doctor" More good drugs have been included in the medical insurance drug list

The National Medical Insurance Bureau recently announced the results of the preliminary examination of the 2022 National Medical Insurance Drug Catalogue, and a total of 344 drugs passed the preliminary formal examination, and the number of declared and approved drugs increased
compared with last year.
The analysis pointed out that since the establishment of the dynamic adjustment mechanism, more good drugs have been included in the medical insurance drug catalog, and the shortcomings of the protection of tumor drugs, rare diseases and children's drugs have been gradually filled, and the negotiation price reduction and medical insurance reimbursement have reduced the drug burden
of patients and families.
According to reports, the adjustment of the medical insurance drug list is divided into enterprise declaration, formal review, expert review, negotiation and bidding, etc.
, through the formal review, it shows that the drug is eligible to enter the next step of expert review.

The adjustment of the national medical insurance information platform received a total of 537 enterprise declarations involving 490 drugs, and 344 drugs passed the preliminary formal examination, with a passing ratio of 70%.

In the results announced this time, there are currently 199 products outside the list that are not included in medical insurance and are expected to be included, and the new crown oral drugs, rare disease treatment drugs, tumor innovative drugs, etc.
have aroused concern, of which the first domestic new crown oral drug "Azfedine tablets" has passed the preliminary form review
.
The National Medical Insurance Bureau said that it will carry out follow-up work in accordance with the procedures and strive to officially include it in the medical insurance directory
at a reasonable price.
Since its establishment, the National Medical Insurance Bureau has adjusted the medical insurance drug catalogue for four consecutive years, accumulatively including 507 new drugs and good drugs, transferring 391 drugs with inaccurate efficacy, increasing the current version of the medical insurance catalogue to 2860 western medicines and proprietary Chinese medicines, and gradually making up for
the shortcomings of oncology drugs, chronic diseases, rare diseases and children's drugs.
In order to crack the "expensive medical treatment", the National Medical Insurance Bureau has added a total of 250 drugs to the list through negotiations, and the average price reduction is more than 50%.

In 2021, during the agreement period, 140 million people were reimbursed for 221 negotiated drugs, and through negotiated price reductions and medical insurance reimbursements, a total of 149.
5 billion yuan
was reduced for patients during the year.
Li Bin, deputy director of the National Health Commission, said at a press conference held on September 7 that in the past decade, the number of people insured by China's basic medical insurance has exceeded 1.
36 billion, and the coverage rate has been stable at more than
95%.
At present, the annual revenue and expenditure of the fund exceeds 2 trillion yuan, benefiting more than 4 billion people
seeking medical treatment.
In the past ten years, the proportion of personal health expenditure of urban and rural residents in China has dropped from 34.
34% in 2012 to 27.
7%, the proportion of medical insurance reimbursement has continued to increase, and the per capita financial subsidy standard of resident medical insurance has been raised from 240 yuan to 610 yuan, benefiting 1 billion urban and rural residents
.
At the same time, the role of medical insurance coverage on the entire pharmaceutical market is also huge, which is of great benefit to the transformation of pharmaceutical research and development and innovative achievements, and it can be said that it is a "virtuous circle"
in medical security.
Pharmaceutical enterprise health standard medicine